Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (192)	6/26/1999 6:17:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 233

Just a quick look on the recap site shows that SmithKline was into that deal for 32.5M--I suppose a person could sort through all the quarterly reports and see just what milestones were met, and how much was spent on the trial... Don't know how long that trial took, impetigo--I was not following magn for a couple years. But it wont take long for an answer to pop up, either here or on the Yahoo thread. If pex fails, expect the burn rate to come down quite a bit, I cant see them launching a whole new trial. And I don't see how the FDA is going to ask for "better control". Maybe I am dense, but if the stuff is as good as oral antibiotics, I think you have to add it to the arsenal. Everything that I heard on the vcall sounded positive, hope I have not deluded myself. Have you listened to the vcall tape?

To: Bob Swift who wrote (192)	6/26/1999 6:46:00 PM
From: Shlepper	Read Replies (2) \| Respond to of 233

Hi Bob, I know I've seen you on other threads. Welcome here. Your questions are good. With over 1000 involved in the study - by far the largest ever in trials involving diabetic foot ulcers, safety and efficacy of Locilex has not been disputed. The issue must still be resolved by the FDA regarding the use of placebos rather than oral antibiotics as the control. The FDA designed the study with no placebo control, and the FDA advisory panel rejected this approach. The cost for conducting the trials was considerable - though softened by SKB milestone payments. There's no way of telling how big a study the FDA would require for placebo controls should they take that route. If you look at the SKB homepage, they have high hopes for Locilex - and may continue to support the effort. Having said all of this, I cannot fathom the FDA requiring additional review with placebo controls. They felt it was unethical when the study was first designed, and it would be hard to justify reversing that decision. The advisory panel clearly erred. I'm not unhappy with the current price of the stock. I'll continue buying at these low prices. The stock has already factored in the advisory panel decision and with an FDA approval, the stock should jump back up to the 5 to 9 level. In the meantime, the squalamine and asthma genomes should continue to boost the stock. I believe that there is sufficient resources for the company to progress on all fronts, though if Locilex is rejected or requires additional high cost testing, then Magainin will need to do more creative partnering and licensing to maintain their operation.